Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 12:30:34 2024-03-28 pm EDT 5-day change 1st Jan Change
42.72 USD +0.08% Intraday chart for Baxter International Inc. +1.67% +10.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Baxter International Files Definitive Proxy Statement with Securities and Exchange Commission CI
Baxter International Receives a Shareholder Proposal from John Chevedden CI
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data RE
Baxter International Now Considering Sale of Kidney Care Business to Private Equity Investors MT
Dialysis firms gain as Ozempic kidney trial data disappoints RE
Transcript : Baxter International Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 04:00 PM
Baxter International Provides an Update on the Planned Separation of its Kidney Care Business CI
Transcript : Baxter International Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 11:00 AM
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years MT
Spectral Medical Announcing "Major Milestone" by Reaching Its Interim Enrollment Target of 90 Patients MT
Baxter International Maintains Quarterly Dividend at $0.29 a Share, Payable April 1 to Shareholders of Record March 1 MT
Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024 CI
UBS Adjusts Baxter International Price Target to $42 From $40, Maintains Neutral Rating MT
Deutsche Bank Adjusts Baxter International Price Target to $42 From $35, Maintains Hold Rating MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1, 2024 Earnings Forecasts MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1 and 2024 Earnings Outlook; Shares Drop MT
Sector Update: Health Care Stocks Steady Premarket Thursday MT
Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1 and 2024 Earnings Outlook; Shares Drop MT
Baxter International to Seek Strategic Acquisitions CI
Transcript : Baxter International Inc., Q4 2023 Earnings Call, Feb 08, 2024
(BAX) BAXTER INTERNATIONAL Forecasts Q1 EPS Range $0.59 - $0.62 MT
(BAX) BAXTER INTERNATIONAL Forecasts Fiscal Year 2024 EPS Range $2.85 - $2.95 MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q4 Revenue $3.89B MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q4 EPS $0.88 MT
Baxter International Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Chart Baxter International Inc.
More charts
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
42.69 USD
Average target price
47.2 USD
Spread / Average Target
+10.56%
Consensus